ArticleCancer immunology, immunotherapy : CII2023

First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study).

Renaud Descourt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.